Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;19(2):77-78.
doi: 10.1038/s41577-018-0103-6.

Advancing an HIV vaccine; advancing vaccinology

Dennis R Burton  1   2
Affiliations
Review

Advancing an HIV vaccine; advancing vaccinology

Dennis R Burton. Nat Rev Immunol. 2019 Feb.

Abstract

Of any pathogen, HIV provides perhaps the greatest challenge to successful vaccine development. Nevertheless, progress continued to be made in 2018; new vaccine concepts entered the clinic and new insights were obtained in basic research that will ultimately help to guide rational vaccine design against many’difficult’ pathogens.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The author declares no competing interests.

Figures

Fig. 1 |
Fig. 1 |. A sequential HIV immunization strategy.
Broadly neutralizing antibodies (bnAbs) isolated from infected individuals provide proof of principle that a bnAb-based HIV vaccine is possible. The bnAbs define vaccine targets on native HIV Envelope (Env) trimers (red). Inferred precursors of the bnAbs (often referred to as inferred germline bnAbs) do not generally bind to native trimers, requiring the design of immunogens to activate precursor bnAb B cells (germline-targeting immunogens, for example, eOD-GT8 (yellow)). In order to shepherd the antibody response towards mature bnAbs, a series of immunogens with increasing native trimer-like features are used; these immunogens can be validated by antibodies derived from bnAbs but of lower potency or breadth. Finally, immunization is carried out with native-like trimers such as SOSIP trimers. Immunogen testing uses animal models expressing bnAb precursor B cells (knock-in mice) or human antibody repertoires before moving into the clinic.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Escolano A, Dosenovic P & Nussenzweig MC Progress toward active or passive HIV-1 vaccination. J. Exp. Med 214, 3–16 (2017). - PMC - PubMed
    1. HIV Prevention Trials Network & HIV Vaccine Trials Network. AMP HIV Prevention Study. AMP Study https://ampstudy.org (2018).
    1. Andrabi R, Bhiman JN & Burton DR Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr. Opin. Immunol 53, 143–151 (2018). - PMC - PubMed
    1. Xu K et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med 24, 857–867 (2018). - PMC - PubMed
    1. Jardine JG et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351, 1458–1463 (2016). - PMC - PubMed